Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$32.43 +0.74%

+$0.18 today

Market cap
$1.77B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 1.00M

Average 0.84M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$111.94M

FY 2025 · Annual

Investing Cash Flow

-$170.96M

FY 2025 · Annual

Financing Cash Flow

$275.34M

FY 2025 · Annual

+196.5% YoY

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(114.94M)(100.42M)52.23M(131.12M)
Depreciation & Amortization3.82M4.09M3.3M2.4M
Deferred Income Tax0000
Stock-Based Compensation6.74M8.75M9.65M16.4M
Change in Working Capital(3.24M)(6.32M)(1.52M)(2.27M)
Accounts Receivables0000
Inventory0000
Accounts Payables(3.78M)399K(204K)(27K)
Other Working Capital541K(6.72M)(1.32M)(2.25M)
Other Non-Cash Items8.42M7.07M12.3M2.65M
Operating Cash Flow(99.2M)(86.83M)75.95M(111.94M)
Capital Expenditures(1.97M)(441K)(1.15M)(794K)
Acquisitions (Net)(1.2M)000
Purchases of Investments000(187.67M)
Sales of Investments00017.5M
Other Investing Activities0000
Investing Cash Flow(3.17M)(441K)(1.15M)(170.96M)
Debt Repayment016.18M24.48M0
Common Stock Issued1.73M209K68.37M275.84M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities000(500K)
Financing Cash Flow1.73M16.39M92.85M275.34M
Effect of Forex Changes0000
Net Change in Cash(100.65M)(70.88M)167.65M(7.57M)
Free Cash Flow(101.17M)(87.27M)74.81M(112.73M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$131.1M
+ D&A$2.4M
+ Stock-Based Comp$16.4M
+ Deferred Tax$0
- Working Capital-$2.3M
+ Other Non-Cash$2.6M
= Operating Cash Flow-$111.9M
- Capex-$794.0K
= Free Cash Flow-$112.7M

Analysis

FY2025 free cash flow is -$112.7M. FCF conversion is 86.0% of net income. Operating cash flow was -$111.9M, with capex of -$794.0K. The largest bridge item is Stock-Based Comp at $16.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
8-KCurrent reportOct 16, 2026

Does MAZE generate free cash flow?

Maze Therapeutics, Inc. (MAZE) generated -$112.73M of free cash flow in fiscal 2025.

How much operating cash flow does MAZE produce?

Operating cash flow was -$111.94M, before capital expenditures of $794,000.00.